Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Immune Design's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Immune Design (IMDZ) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q1 2018
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
-1.86 %
Q1 2018
Net Margin
-2,857.35 %
Q1 2018

Key Findings: Immune Design vs Its Competitors

  • TTM: Trailing 12-month revenue of 2M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is decelerating (-13.3% annualized vs trailing 12 months).
  • Peer revenue share: Immune Design accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

IMDZ Sales vs. its Competitors, Q1 2018

Immune Design generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IMDZ/competitors
https://api.csimarket.com/api/v1/companies/IMDZ/relationships
https://api.csimarket.com/api/v1/companies/IMDZ/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API

For context: the Major Pharmaceutical Preparations industry grew revenue 8.8% year over year, combined, vs -1.9% for Immune Design. Immune Design's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.

Immune Design's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Immune Design Corp. - No No No
High-Confidence Competitors (131) 41% 68% 56% 57%

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q1 2018

100%market share
  • Immune Design100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Immune Design and its 0 tracked competitors.

See Immune Design's full market share breakdown »

IMDZ Stock Performance relative to its Competitors

IMDZ Competitors (weighted) Percent change over the selected range

Immune Design's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
36.9%beat U.S.A. 500
High-Confidence
(41 of 111)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Immune Design Corp. - -
Competitors combined (0) 40.4% 63.2%
High-Confidence Competitors (111) 40.4% 63.2%
Similar-Size Competitors (0) 40.4% 63.2%
Similar Growth & Profitability (0) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Immune Design's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

IMDZ Stock Performance relative to High-Confidence Competitors

IMDZ High-Confidence Competitors (equal-weighted, 138) Percent change over the selected range

Immune Design's Competitors Named by the Company

Competitive relationships identified from Immune Design reports and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Novartis International AG Company report 85% 2022 to 2026 3
AstraZeneca plc Company report 85% 2022 to 2026 3
Keros Therapeutics Inc Company report 85% 2022 to 2026 3
Janux Therapeutics Inc Company report 85% 2022 to 2026 3
Cytomx Therapeutics Inc Company report 85% 2022 to 2026 3
Eli Lilly And Company Company report 85% 2022 to 2026 3
Gilead Sciences Inc Company report 85% 2022 to 2026 3
Pfizer Inc. Company report 85% 2022 to 2026 3
Greenwich Lifesciences Inc Company report 85% 2022 to 2026 3
Bayer AG Company report 85% 2022 to 2026 3
Marker Therapeutics inc Company report 85% 2022 to 2026 3
Mirati Therapeutics Inc Company report 85% 2022 to 2026 3
Propanc Biopharma Inc Company report 85% 2022 to 2026 3
Agentix Corp Company report 85% 2022 to 2026 3
Briacell Therapeutics Corp Company report 85% 2022 to 2026 3
Petvivo Holdings Inc Company report 85% 2022 to 2026 3
Abivax Sa Company report 85% 2022 to 2026 3
Agomab Therapeutics Nv Company report 85% 2022 to 2026 3
Palatin Technologies Inc Company report 85% 2022 to 2026 3
Elanco Animal Health Incorporated Company report 85% 2022 to 2026 3
Allarity Therapeutics Inc Company report 85% 2022 to 2026 3
Sunshine Biopharma Inc Company report 85% 2022 to 2026 3
Oragenics Inc Company report 85% 2022 to 2026 3
Terns Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Absci Corp Company report 85% 2022 to 2026 3
Vaxcyte Inc Company report 85% 2022 to 2026 3
Compass Therapeutics Inc Company report 85% 2022 to 2026 3
Protagonist Therapeutics inc Company report 85% 2022 to 2026 3
Cue Biopharma Inc Company report 85% 2022 to 2026 3
Qnity Electronics Inc Company report 85% 2022 to 2026 3
Mangoceuticals Inc Company report 85% 2022 to 2026 3
Sagimet Biosciences inc Company report 85% 2022 to 2026 3
Bnb Plus Corp Company report 85% 2022 to 2026 3
Northwest Biotherapeutics Inc Company report 85% 2022 to 2026 3
Calidi Biotherapeutics Inc Company report 85% 2022 to 2026 3
Tempest Therapeutics Inc Company report 85% 2022 to 2026 3
Puretech Health Plc Company report 85% 2022 to 2026 3
Voyager Therapeutics Inc Company report 85% 2022 to 2026 3
Mosaic Immunoengineering Inc Company report 85% 2022 to 2026 3
Maia Biotechnology Inc Company report 85% 2022 to 2026 3
Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Immune Design's named competitors require a Commercial License.

Methodology: relationships are extracted from Immune Design reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.

Get the full CSIMarket dataset: Subscribe API Connect Your AI